Dreymueller Daniela, Goetzenich Andreas, Emontzpohl Christoph, Soppert Josefin, Ludwig Andreas, Stoppe Christian
Institute of Pharmacology and Toxicology, University Hospital, RWTH Aachen University, Aachen, Germany.
Department for Thoracic and Cardiovascular Surgery, University Hospital, RWTH Aachen University, Aachen, Germany.
J Cell Mol Med. 2016 Jan;20(1):104-15. doi: 10.1111/jcmm.12708. Epub 2015 Oct 23.
The chemokine CXCL16 and its receptor CXCR6 have been linked to the pathogenesis of acute and chronic cardiovascular disease. However, data on the clinical significance of CXCL16 in patients undergoing cardiac surgery with acute myocardial ischemia/reperfusion (I/R) are still lacking. Therefore, we determined CXCL16 in the serum of cardiac surgery patients and investigated its kinetics and association with the extent of organ dysfunction. 48 patients underwent conventional cardiac surgery with myocardial I/R and the use of cardiopulmonary bypass (CPB) were consecutively enrolled in the present study. We investigated the peri- and post-operative profile of CXCL16. Clinical relevant data were assessed and documented throughout the entire observation period. To identify the influence of myocardial I/R and CPB on CXCL16 release data were compared to those received from patients that underwent off-pump procedure. Pre-operative serum CXCL16 levels were comparable to those obtained from healthy volunteers (1174 ± 55.64 pg/ml versus 1225 ± 70.94). However, CXCL16 levels significantly increased during surgery (1174 ± 55.64 versus 1442 ± 75.42 pg/ml; P = 0.0057) and reached maximum levels 6 hrs after termination of surgery (1174 ± 55.64 versus 1648 ± 74.71 pg/ml; P < 0.001). We revealed a positive correlation between the intraoperative serum levels of CXCL16 and the extent of organ dysfunction (r(2) = 0.356; P = 0.031). Patients with high CXCL16 release showed an increased extent of organ dysfunction compared to patients with low CXCL16 release. Our study shows that CXCL16 is released into the circulation as a result of cardiac surgery and that high post-operative CXCL16 levels are associated with an increased severity of post-operative organ dysfunctions.
趋化因子CXCL16及其受体CXCR6与急慢性心血管疾病的发病机制有关。然而，关于CXCL16在急性心肌缺血/再灌注（I/R）心脏手术患者中的临床意义的数据仍然缺乏。因此，我们测定了心脏手术患者血清中的CXCL16，并研究了其动力学以及与器官功能障碍程度的关联。本研究连续纳入了48例行常规心肌I/R心脏手术并使用体外循环（CPB）的患者。我们研究了CXCL16在围手术期和术后的情况。在整个观察期内评估并记录临床相关数据。为了确定心肌I/R和CPB对CXCL16释放的影响，将数据与接受非体外循环手术的患者的数据进行比较。术前血清CXCL16水平与健康志愿者的水平相当（1174±55.64 pg/ml对1225±70.94）。然而，CXCL16水平在手术期间显著升高（1174±55.64对1442±75.42 pg/ml；P = 0.0057），并在手术结束后6小时达到最高水平（1174±55.64对1648±74.71 pg/ml；P < 0.001）。我们发现术中血清CXCL16水平与器官功能障碍程度呈正相关（r(2)=0.356；P = 0.031）。与CXCL16释放水平低的患者相比，CXCL16释放水平高的患者器官功能障碍程度增加。我们的研究表明，CXCL16因心脏手术而释放到循环中，术后CXCL16高水平与术后器官功能障碍的严重程度增加有关。
